MXPA01009035A - Terapia de combinacion de inhibidor de enzima convertidora de angiotensina y antagonista de aldosterona epoxi-esteroidea para tratamiento de enfermedad cardiovascular. - Google Patents
Terapia de combinacion de inhibidor de enzima convertidora de angiotensina y antagonista de aldosterona epoxi-esteroidea para tratamiento de enfermedad cardiovascular.Info
- Publication number
- MXPA01009035A MXPA01009035A MXPA01009035A MXPA01009035A MXPA01009035A MX PA01009035 A MXPA01009035 A MX PA01009035A MX PA01009035 A MXPA01009035 A MX PA01009035A MX PA01009035 A MXPA01009035 A MX PA01009035A MX PA01009035 A MXPA01009035 A MX PA01009035A
- Authority
- MX
- Mexico
- Prior art keywords
- epoxy
- treatment
- converting enzyme
- angiotensin converting
- enzyme inhibitor
- Prior art date
Links
- 239000005541 ACE inhibitor Substances 0.000 title abstract 3
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 title abstract 3
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 title abstract 2
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 title abstract 2
- 229940083712 aldosterone antagonist Drugs 0.000 title abstract 2
- 239000002170 aldosterone antagonist Substances 0.000 title abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 abstract 2
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 abstract 2
- 239000002464 receptor antagonist Substances 0.000 abstract 2
- 229940044551 receptor antagonist Drugs 0.000 abstract 2
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 208000002682 Hyperkalemia Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000011262 co‐therapy Methods 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- -1 eplerenone Chemical class 0.000 abstract 1
- 229960001208 eplerenone Drugs 0.000 abstract 1
- JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical compound C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/556—Angiotensin converting enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Microbiology (AREA)
- Vascular Medicine (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Abstract
Las combinaciones de un inhibidor de enzima convertidora de angiotensina y un antagonista receptor de aldosterona epoxi-esteroidea se describen para utilizarse en el tratamiento de trastornos circulatorios; las terapias que emplean compuestos de antagonistas eceptores de aldosterona tipo epoxi-esteroidea, tales como eplerenona en combinacion con un inhibidor de enzima convertidora de angiotensina, son de interes particular; esta co-terapia resultaria util en particular para tratar insuficiencia cardiaca congestiva, mientras que tambien evita o reduce los efectos secundarios inducidos por antagonistas de aldosterona, tales como hipercalemia.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12297799P | 1999-03-05 | 1999-03-05 | |
| PCT/US2000/005633 WO2000051642A1 (en) | 1999-03-05 | 2000-03-03 | Combination therapy of angiotensin converting enzyme inhibitor and epoxy-steroidal aldosterone antagonist for treatment of cardiovascular disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA01009035A true MXPA01009035A (es) | 2004-08-12 |
Family
ID=22406014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA01009035A MXPA01009035A (es) | 1999-03-05 | 2000-03-03 | Terapia de combinacion de inhibidor de enzima convertidora de angiotensina y antagonista de aldosterona epoxi-esteroidea para tratamiento de enfermedad cardiovascular. |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20040077611A1 (es) |
| EP (2) | EP1165136B1 (es) |
| JP (1) | JP2002538172A (es) |
| KR (1) | KR100580286B1 (es) |
| CN (1) | CN1229141C (es) |
| AR (1) | AR029155A1 (es) |
| AT (2) | ATE249242T1 (es) |
| AU (2) | AU778559B2 (es) |
| BR (1) | BR0008781A (es) |
| CA (1) | CA2364169A1 (es) |
| DE (2) | DE60024335T2 (es) |
| DK (2) | DK1382351T3 (es) |
| EA (1) | EA004064B1 (es) |
| ES (2) | ES2206204T3 (es) |
| HK (1) | HK1042252B (es) |
| HU (1) | HUP0200519A2 (es) |
| IL (2) | IL145237A0 (es) |
| MX (1) | MXPA01009035A (es) |
| NZ (1) | NZ514205A (es) |
| PT (1) | PT1165136E (es) |
| SI (1) | SI1165136T1 (es) |
| TR (1) | TR200102581T2 (es) |
| WO (1) | WO2000051642A1 (es) |
| ZA (1) | ZA200107779B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA01008056A (es) * | 1999-12-08 | 2003-07-21 | Pharmacia Corp | Forma cristalina de eplerenona que exhibe velocidad de disolucion intensificada. |
| EP1505072A3 (en) * | 1999-12-08 | 2006-06-21 | Pharmacia Corporation | Eplerenone crystalline form exhiniting enhanced dissolution rate |
| EP1580193A3 (en) * | 1999-12-08 | 2010-06-23 | Pharmacia Corporation | Eplerenone crystalline form |
| CN100413881C (zh) * | 1999-12-08 | 2008-08-27 | 法马西亚公司 | 依匹乐酮晶形 |
| US20010039262A1 (en) * | 2000-04-26 | 2001-11-08 | Balaji Venkataraman | Methods and compositions for the treatment of cardiac indications |
| CA2419256A1 (en) * | 2000-08-28 | 2002-03-07 | Kenton N. Fedde | Use of an aldosterone receptor antagonist to improve cognitive function |
| WO2006119779A2 (en) * | 2005-05-10 | 2006-11-16 | Lifecycle Pharma A/S | A pharmaceutical composition comprising an aldosterone antagonist in form of solid solution |
| US20100028439A1 (en) * | 2005-05-23 | 2010-02-04 | Elan Pharma International Limited | Nanoparticulate stabilized anti-hypertensive compositions |
| US20070112593A1 (en) * | 2005-11-14 | 2007-05-17 | Rxcera Pharmaceutical, Inc. | Selection system, dispensing system and treatment with a one-a-day combination pill for hypertension, hypercholesterolemia, hypertriglyceridemia and anti-platelet treatment |
| US20100318371A1 (en) * | 2009-06-11 | 2010-12-16 | Halliburton Energy Services, Inc. | Comprehensive hazard evaluation system and method for chemicals and products |
| WO2014018930A1 (en) * | 2012-07-27 | 2014-01-30 | Isis Pharmaceuticals. Inc. | Modulation of renin-angiotensin system (ras) related diseases by angiotensinogen |
| CN106267147A (zh) * | 2015-06-10 | 2017-01-04 | 上药东英（江苏）药业有限公司 | 一种复方降压药物组合物 |
| MY200263A (en) | 2015-10-08 | 2023-12-18 | Ionis Pharmaceuticals Inc | Compounds and methods for modulating angiotensinogen expression |
| LT4136092T (lt) | 2020-11-18 | 2024-09-25 | Ionis Pharmaceuticals, Inc. | Junginiai ir būdai, skirti angiotenzinogeno raiškos moduliavimui |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6039296A (en) * | 1995-06-07 | 1996-12-30 | G.D. Searle & Co. | Method to treat cardiofibrosis with a combination therapy of an angiotensin ii antagonist and an epoxy-steroidal aldoste rone antagonist |
| CN1142793C (zh) * | 1995-06-07 | 2004-03-24 | G·D·瑟尔公司 | 环氧-甾族化合物醛甾酮拮抗剂和血管紧张肽ⅱ拮抗剂联合治疗用于治疗充血性心衰 |
-
2000
- 2000-03-03 AR ARP000100977A patent/AR029155A1/es unknown
- 2000-03-03 ES ES00912174T patent/ES2206204T3/es not_active Expired - Lifetime
- 2000-03-03 DK DK03019610T patent/DK1382351T3/da active
- 2000-03-03 EP EP20000912174 patent/EP1165136B1/en not_active Expired - Lifetime
- 2000-03-03 IL IL14523700A patent/IL145237A0/xx active IP Right Grant
- 2000-03-03 MX MXPA01009035A patent/MXPA01009035A/es active IP Right Grant
- 2000-03-03 AT AT00912174T patent/ATE249242T1/de not_active IP Right Cessation
- 2000-03-03 TR TR2001/02581T patent/TR200102581T2/xx unknown
- 2000-03-03 JP JP2000602308A patent/JP2002538172A/ja not_active Withdrawn
- 2000-03-03 CN CNB008071888A patent/CN1229141C/zh not_active Expired - Fee Related
- 2000-03-03 EA EA200100951A patent/EA004064B1/ru unknown
- 2000-03-03 ES ES03019610T patent/ES2250803T3/es not_active Expired - Lifetime
- 2000-03-03 SI SI200030232T patent/SI1165136T1/xx unknown
- 2000-03-03 DK DK00912174T patent/DK1165136T3/da active
- 2000-03-03 KR KR1020017011322A patent/KR100580286B1/ko not_active Expired - Fee Related
- 2000-03-03 HU HU0200519A patent/HUP0200519A2/hu unknown
- 2000-03-03 DE DE60024335T patent/DE60024335T2/de not_active Expired - Fee Related
- 2000-03-03 WO PCT/US2000/005633 patent/WO2000051642A1/en not_active Ceased
- 2000-03-03 AU AU33945/00A patent/AU778559B2/en not_active Ceased
- 2000-03-03 PT PT00912174T patent/PT1165136E/pt unknown
- 2000-03-03 HK HK02104154.2A patent/HK1042252B/en not_active IP Right Cessation
- 2000-03-03 DE DE60005159T patent/DE60005159T2/de not_active Expired - Fee Related
- 2000-03-03 EP EP03019610A patent/EP1382351B8/en not_active Expired - Lifetime
- 2000-03-03 AT AT03019610T patent/ATE310537T1/de not_active IP Right Cessation
- 2000-03-03 BR BR0008781-5A patent/BR0008781A/pt not_active IP Right Cessation
- 2000-03-03 CA CA002364169A patent/CA2364169A1/en not_active Abandoned
- 2000-03-03 NZ NZ514205A patent/NZ514205A/en unknown
-
2001
- 2001-09-03 IL IL145237A patent/IL145237A/en not_active IP Right Cessation
- 2001-09-20 ZA ZA200107779A patent/ZA200107779B/en unknown
-
2003
- 2003-05-19 US US10/440,691 patent/US20040077611A1/en not_active Abandoned
-
2005
- 2005-03-09 AU AU2005201045A patent/AU2005201045A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA01009035A (es) | Terapia de combinacion de inhibidor de enzima convertidora de angiotensina y antagonista de aldosterona epoxi-esteroidea para tratamiento de enfermedad cardiovascular. | |
| HK1040056A1 (zh) | 血管紧张肽转换酶抑制剂及醛甾䣳对抗物的综合治疗以减低心血管疾病的发病率及死亡率 | |
| EP1059100A3 (en) | Combinations of CRF antagonists and renin-angiotensin system inhibitors | |
| SG149027A1 (en) | Substituted urea derivatives for treating cardiac diseases | |
| SG155188A1 (en) | Pyrrole derivatives as pharmaceutical agents | |
| IL181629A0 (en) | Compositions and methods for the diagnosis and tretment of tumor | |
| AU3920900A (en) | Compounds and methods to treat cardiac failure and other disorders | |
| ZA200600679B (en) | Therapeutic compounds | |
| WO2008017025A3 (en) | Combination therapy | |
| TW200740803A (en) | Heterocyclic derivatives as modulators of ion channels | |
| AU2003220299A1 (en) | Azinylaminoazoles as inhibitors of protein kinases | |
| BR9604882A (pt) | Terapia de combinação de inibidor de enzima de conversão de antgiotensina e quantidade de efeito colateral reduzido de antagonista de aldosterona para tratamento de doença cardiovascular | |
| WO2010045575A3 (en) | Compositions and methods for treatment of renin-angiotensin aldosterone system (raas)-related disorders | |
| SI1546182T1 (sl) | Sestavki in postopki za diagnozo in zdravljenje tumorja | |
| MX2007005367A (es) | Uso de ranolazina en combinacion con por lo menos un agente de remodelacion para revertir la remodelacion ventricular izquierda en el tratamiento de la insuficiencia cardiaca. | |
| AU2001282990A1 (en) | Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders | |
| WO2003094967A3 (en) | New combination of reversible proton pump inhibitors and airway therapeutics for treating airway disorders | |
| WO2004030623A3 (en) | Nitroxide radioprotector formulations and methods of use | |
| PL371436A1 (en) | Aldosterone antagonist and non-steroidal anti-inflammatory agent combination therapy to prevent or treat cardiovascular disorders | |
| PL373391A1 (en) | Aldosterone blocker therapy to prevent or treat inflammation-related disorders | |
| AR021106A1 (es) | Terapia combinada de un inhibidor de la enzima convertidora de angiotensina y un antagonista de aldosterona para reducir la morbilidad y mortalidad porenfermedades cardiovasculares | |
| WO2004004640A3 (en) | Methods, compositions and kits for treating damage to excitable tissue | |
| Barman et al. | Exercise-induced ventricular arrhythmias in congestive heart failure and role of ARB | |
| IT1312003B1 (it) | Uso di lonidamina e suoi derivati nel trattamento di affezioni causateda retrovirus. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |